Form 4: Corcept Therapeutics Director Daniel N. Swisher, Jr. Reports Stock Transactions

Director Daniel N. Swisher, Jr. of Corcept Therapeutics reports the exercise of stock options and subsequent sale of shares on August 1, 2024.

Summary

• On August 1, 2024, Daniel N. Swisher, Jr., a director of Corcept Therapeutics, exercised stock options to acquire 150 shares of common stock at a price of $5.86 per share.
• Following the acquisition, Swisher sold 150 shares of common stock at a price of $38.50 per share.
• The sale was executed under a pre-existing 10b5-1 trading plan.
• After these transactions, Swisher holds no shares of common stock.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of stock transactions by a company director. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders, such as directors and officers, trade their company's stock. These filings provide transparency into insider transactions and are closely monitored by investors for insights into management's perspective on the company's value and prospects.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly traded companies.
• The use of 10b5-1 trading plans is a standard practice to allow insiders to sell shares without being accused of trading on non-public information.
• Comparing Swisher's transactions to those of other directors in similar pharmaceutical companies could provide a benchmark, but this would require analyzing additional Form 4 filings.

Stakeholder Impact

• The transactions may have a minor impact on shareholders as they provide insight into insider sentiment.
• The impact on other stakeholders (employees, customers, suppliers, creditors) is likely negligible.

Key Dates